Download
unprecedented growth opportunity n.
Skip this Video
Loading SlideShow in 5 Seconds..
Unprecedented Growth Opportunity PowerPoint Presentation
Download Presentation
Unprecedented Growth Opportunity

Unprecedented Growth Opportunity

111 Vues Download Presentation
Télécharger la présentation

Unprecedented Growth Opportunity

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Unprecedented Growth Opportunity BIOTECHNOLOGY

  2. Biotechnology • India - An Overview • Market and Growth Potential • Players • Opportunities • Why India? • Contact in India

  3. India - An Introduction Over 1 bn 35 3.3 mn sq kms 22 English US$ 534 US$ 650 bn • Population • States/UTs • Geographical Area • Languages recognised • Business language • Per Capita Income** • GDP** **(at factor cost & at current prices) 1USD=43.54 INR (as on July 4, 2005) Source:CSO Statistics

  4. India - Fast pace Growth • Largest democracy • 4th largest economy by PPP index • 6th largest energy consumer • ForEx reserves skyrocket from US$ 42 bn (2001) to US$ 133 bn (February, 2005) • GDP growth to continue between 6-8% • 3rd largest economy by 2050: Goldman Sachs • Leading in IT & BPO • Oil & Gas and Biotechnology sunrise industries

  5. India - Leading the world • Hero Honda - largest manufacturer of motorcycles • Moser Baer - 3rd largest optical media manufacturer in world • Pharmaceutical Industry - 4th largest in world • Walmart, GAP, Hilfiger sources more than USD 1bn worth apparel from India • 100 Fortune 500 have set R&D facilities in India including GE, Delphi, Eli Lilly, HP, Heinz and Daimler Chrysler

  6. Biotechnology • India - An Overview • Market and Growth Potential • Players • Opportunities • Why India? • Contact in India

  7. Biotech Market - Dynamic and growing • Size (2004-05) US$ 1090.5 mn • Largest segment Biopharma • Revenue from exports (2003-04) 56% • Total investment (2003-04) US$ 137 million Rate of growth over 202-2003 26%

  8. Biopharma leads the way Bio Agri Bio-IT 6.95% 2.09 % Bio Services 8.95% Bio Pharma 75.24 % Composition of Indian Biotech Sector (2004-05) Bio Industrial 6.74% Source:Biospectrum-ABLE Survey

  9. Market - A consistent uptrend 25% growth in investment 2002-03 70% growth in employment 74% growth in R&D manpower US$ 5 billion annual revenues 2010 1 million skilled jobs 10% of global industry Source: Confederation of Indian Industry (CII)

  10. Biotechnology • India - An Overview • Market and Growth Potential • Players • Opportunities • Why India? • Contact in India

  11. Indian Players

  12. MNCs Scripting Success in India

  13. Biotechnology • India - An Overview • Market and Growth Potential • Players • Opportunities • Why India? • Contact in India

  14. Investments • Annual investments in this sector will be of the order of US$ 150 mn and are growing at the rate of 25%. • An additional investment of US$ 216 mn is expected in FY2005

  15. Invest in Biopharmaceuticals • Vaccine Sales of US$ 383.6 mn (2004-05) • Therapeutic Marketing licenses granted for over 25 recombinant therapeutic proteins • Diagnostics Sales market - US$ 138.2 mn (2004-05)

  16. India: The Vaccine Hub • Indian firms estimated to supply 90% of global demand for the measles vaccine, in the near future. • Serum Institute, Pune is believed to be the world`s largest manufacturer of DPT vaccines. • Indian Immunologicals operates the world`s second largest plant for veterinary vaccines and is also the world`s largest manufacturer of the vaccine against Foot and Mouth Disease.

  17. Invest in Biopharmaceuticals • Therapeutic Accounts for 14% of total biopharma sales (2004-05) • Diagnostics Forecast to grow by 35-40% in 2005 Immuno diagnostic market to increase 4 to 5 folds by 2005

  18. Invest in Bioinformatics By 2006 bionformatics market to grow 2004-05 US$ 22.9 mn By 2006 US$ 120 mn Source: International Data Corporation (IDC) • Data mining • Gene annotation • Software bioinformatics interface development Opportunities for investment

  19. Invest in Genomics and Industrial Biotech • Genomics • Industrial Biotech • Size (2004-05) US$ 73.5 mn

  20. Invest in Agri Biotech Biofertilisers Biofuels GM Crops and seeds Biopesticides

  21. Invest in Agri Biotech Biofertilisers Biofuels GM Crops and seeds Biopesticides

  22. Clinical Trials - Destination India Quality Speed Technology Disease Profile Investigators Genetic diversity Ethics Quality guidelines conformed Patient enrolment rates upto six times higher than US CROs to benefit from India’s IT strengths in data management High incidence of infectious/lifestyle diseases Excellent pool of qualified & trained doctors and physicians

  23. Biotechnology • India - An Overview • Market and Growth Potential • Players • Opportunities • Why India? • Contact in India

  24. The India Advantage Excellent network of research laboratories Well-developed base industries Rich biodiversity Extensive clinical trials opportunities Trained manpower and knowledge base

  25. The Infrastructure Advantage • 40 National Research Institutes • 300 life sciences colleges • 120 medical colleges • 200 biotech companies • 100 teaching hospitals 15,000 scientists 500,000 graduates per annum 17,500 medical graduates per annum Employing 25,000 scientists in R&D Employing medical & paramedical professionals

  26. The R & D Advantage Genetic Engineering DNA technologies New Drug Delivery Systems Rational drug design Stem cell research Bioinformatics Biotech R&D strengths spread across range of segments

  27. The Policy Advantage • India has transitioned from a process patent regime to a product patent regime w.e.f January, 2005 • 150% weighted deduction on R&D expenditure • Single window application processing proposed by DBT • New biotech proposals to be cleared within 150 days • Formation of a SME Growth Fund to provide equity support to small & medium units in the biotechnology sectors (Union Budget 2005-06)

  28. Union Budget 2005-06 The Biotech Park Advantage • Benefits enjoyed by Export Oriented Units (EOU) extended to Biotech Parks - 100% FDI permitted through automatic route - BTP units exempt from payment of Income Tax - Export proceeds to be realised within 12 months - BTPs allowed to retain 100% export earnings in the EEFC account

  29. Biotechnology • India - An Overview • Market and Growth Potential • Players • Opportunities • Why India? • Contact in India

  30. Contact in India Confederation of Indian Industry (CII) 23 Institutional Area Lodi Road New Delhi 110003 Tel 0091 11 24629994 - 7 Fax 0091 11 24626149/24615693 E-mail sandhya.tewari@ciionline.org